Deflection Protocol: Endocrinology Suite

When the lab panel hits the desk and your only defense is unsolicited pancreatic trivia.

Filed under Retatrutide ·Cagrilintide ·Survodutide · #cope ·#glp-1 ·#stack-life

Active Compounds

Retatrutide · Triple GIP/GLP-1/Glucagon Receptor Agonist

An investigational triple agonist (GIP/GLP-1/glucagon) from Eli Lilly. Not FDA-approved. Phase III TRIUMPH-4 results showed 23.7% weight loss — the most of any obesity drug in development.

Cagrilintide · Amylin Analogue

A long-acting amylin analogue being developed in combination with semaglutide (CagriSema) for enhanced weight loss.

Survodutide · Dual Glucagon/GLP-1 Receptor Agonist

An investigational dual glucagon/GLP-1 receptor agonist from Boehringer Ingelheim and Zealand Pharma. Phase 3 SYNCHRONIZE-1 (April 28, 2026 topline) achieved 16.6% mean weight loss at 76 weeks — the first positive Phase 3 readout in the SYNCHRONIZE obesity program. FDA Fast Track (2021) and Breakthrough Therapy (2024) designations for MASH; full SYNCHRONIZE-1 data at ADA June 2026.

RX: Retatrutide · Cagrilintide · Survodutide
Dosage: one nervous fun fact, SC
Half-life: until she flips the page
Source: manual
Tags: cope , glp-1 , stack-life
Stamped: 2026-09-13 · Cycle 037
Lot #: LOT-20260913T21:14:34.391Z